Lyell Immunopharma's 15min Chart Triggers MACD Death Cross, KDJ Death Cross, Bearish Marubozu

Lyell Immunopharma's 15-minute chart has recently triggered a MACD Death Cross, KDJ Death Cross, and a Bearish Marubozu at 08/15/2025 16:00. This technical indicator suggests that the stock price has the potential to continue its downward trend, as the momentum of the stock price is shifting towards the downside and may further decrease. Sellers currently dominate the market, and the bearish momentum is likely to persist.

Lyell Immunopharma Inc (LYEL) has experienced a significant shift in its stock price momentum, with technical indicators pointing towards a persistent bearish trend. On August 15, 2025, at 16:00, the company's 15-minute chart triggered a MACD Death Cross, KDJ Death Cross, and a Bearish Marubozu, all of which suggest that the stock price may continue to decline [1][2]. This indicates that sellers currently dominate the market, and bearish momentum is likely to persist.

Analysts expect Lyell Immunopharma to report a loss of $3.58 per share for the quarter ending June 30, 2025, which aligns with the company's mixed performance history [1]. The current average analyst rating for the shares is "hold," with no "strong buy" or "buy" recommendations and a single "sell" or "strong sell" recommendation [1]. Wall Street's median 12-month price target for Lyell Immunopharma Inc is $11.00, approximately 3.9% below its last closing price of $11.43 [1].

Technical analysis of Lyell Immunopharma's 15-minute chart reveals several indicators suggesting a bearish trend. The MACD (Moving Average Convergence Divergence) has triggered a death cross, indicating a potential continuation of the stock's downward movement. Additionally, the KDJ (KST Divergence Index) has also triggered a death cross, suggesting a shift in momentum towards the downside. A bearish marubozu candlestick pattern observed on August 15, 2025, at 16:00, further supports the bearish trend, indicating that sellers are in control of the market [2].

Investors should closely monitor the company's earnings release and subsequent market reactions. While the technical indicators suggest a persistent bearish trend, the company's clinical advancements may provide a counterbalance to the financial concerns. However, the overall market sentiment remains cautious.

References:
[1] Reuters. (2025). Lyell Immunopharma Inc expected to post a loss of $3.58 per share. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX3TD:0-lyell-immunopharma-inc-expected-to-post-a-loss-of-3-58-a-share-earnings-preview/
[2] Technical Analysis Report. (2025). Lyell Immunopharma Inc 15-minute Chart Analysis. Retrieved from [source]